Search research articles
Contact Us
Filters
Showing results (1-10 of 186) with videos related to
Page
of 19
Sort By:
Annals of the Rheumatic Diseases
|
May 28, 2020
Eric Bywaters a life story: 1 June 1910 to 2 April 2003
David Isenberg
Current Opinion in Rheumatology
|
December 4, 2004
Making sure the treatment of myositis does not get "lost in translation"
David Isenberg
Arthritis and Rheumatism
|
May 25, 2010
"Muscles … and bones"
David Isenberg
Annals of the Rheumatic Diseases
|
October 31, 2018
Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand <i>et al</i>
David Isenberg
Annals of the Rheumatic Diseases
|
November 5, 2015
Further thoughts about the ILLUMINATE studies of tabalumab in SLE
David Isenberg
Rheumatic Diseases Clinics of North America
|
August 9, 2005
Mixed connective tissue disease: still crazy after all these years
Josephine Swanton, David Isenberg
Current Opinion in Pharmacology
|
July 15, 2004
Anti B cell therapy (rituximab) in the treatment of autoimmune diseases
Hanadi Kazkaz, David Isenberg
Clinical Medicine (London, England)
|
July 11, 2006
Working together to improve rheumatology services
Matthew Adler, David Isenberg
Annals of the Rheumatic Diseases
|
May 22, 2014
Vaccines and biologics
Isabel Ferreira, David Isenberg
Lupus
|
May 26, 2023
A review of the development of gangrene in patients with systemic lupus erythematosus - A 44-year follow-up study
Joana Rua, David Isenberg
Page
of 19
Search research articles
Search
Showing results (1-10 of 186) with videos related to
Sort By:
Page
of 19
Annals of the Rheumatic Diseases
|
May 28, 2020
Eric Bywaters a life story: 1 June 1910 to 2 April 2003
David Isenberg
Current Opinion in Rheumatology
|
December 4, 2004
Making sure the treatment of myositis does not get "lost in translation"
David Isenberg
Arthritis and Rheumatism
|
May 25, 2010
"Muscles … and bones"
David Isenberg
Annals of the Rheumatic Diseases
|
October 31, 2018
Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand <i>et al</i>
David Isenberg
Annals of the Rheumatic Diseases
|
November 5, 2015
Further thoughts about the ILLUMINATE studies of tabalumab in SLE
David Isenberg
Rheumatic Diseases Clinics of North America
|
August 9, 2005
Mixed connective tissue disease: still crazy after all these years
Josephine Swanton, David Isenberg
Current Opinion in Pharmacology
|
July 15, 2004
Anti B cell therapy (rituximab) in the treatment of autoimmune diseases
Hanadi Kazkaz, David Isenberg
Clinical Medicine (London, England)
|
July 11, 2006
Working together to improve rheumatology services
Matthew Adler, David Isenberg
Annals of the Rheumatic Diseases
|
May 22, 2014
Vaccines and biologics
Isabel Ferreira, David Isenberg
Lupus
|
May 26, 2023
A review of the development of gangrene in patients with systemic lupus erythematosus - A 44-year follow-up study
Joana Rua, David Isenberg
Page
of 19